Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Integrative Genomic Characterization Identifies Molecular Subtypes of Lung Carcinoids.

Laddha SV, da Silva EM, Robzyk K, Untch BR, Ke H, Rekhtman N, Poirier JT, Travis WD, Tang LH, Chan CS.

Cancer Res. 2019 Sep 1;79(17):4339-4347. doi: 10.1158/0008-5472.CAN-19-0214. Epub 2019 Jul 12.

PMID:
31300474
2.

Genomic and Transcriptomic Characterization of Papillary Microcarcinomas With Lateral Neck Lymph Node Metastases.

Perera D, Ghossein R, Camacho N, Senbabaoglu Y, Seshan V, Li J, Bouvier N, Boucai L, Viale A, Socci ND, Untch BR, Gonen M, Knauf J, Fagin JA, Berger M, Tuttle RM.

J Clin Endocrinol Metab. 2019 Oct 1;104(10):4889-4899. doi: 10.1210/jc.2019-00431.

PMID:
31237614
3.

Real-Time Genomic Characterization of Metastatic Pancreatic Neuroendocrine Tumors Has Prognostic Implications and Identifies Potential Germline Actionability.

Raj N, Shah R, Stadler Z, Mukherjee S, Chou J, Untch B, Li J, Kelly V, Saltz LB, Mandelker D, Ladanyi M, Berger MF, Klimstra DS, Reidy-Lagunes D, Osoba M.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00267. Epub 2018 Apr 19.

4.

Interinstitutional variation in predictive value of the ThyroSeq v2 genomic classifier for cytologically indeterminate thyroid nodules.

Marcadis AR, Valderrabano P, Ho AS, Tepe J, Swartzwelder CE, Byrd S, Sacks WL, Untch BR, Shaha AR, Xu B, Lin O, Ghossein RA, Wong RJ, Marti JL, Morris LGT.

Surgery. 2019 Jan;165(1):17-24. doi: 10.1016/j.surg.2018.04.062. Epub 2018 Oct 22.

PMID:
30360906
5.

ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup.

Chan CS, Laddha SV, Lewis PW, Koletsky MS, Robzyk K, Da Silva E, Torres PJ, Untch BR, Li J, Bose P, Chan TA, Klimstra DS, Allis CD, Tang LH.

Nat Commun. 2018 Oct 12;9(1):4158. doi: 10.1038/s41467-018-06498-2.

6.

Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers.

Untch BR, Dos Anjos V, Garcia-Rendueles MER, Knauf JA, Krishnamoorthy GP, Saqcena M, Bhanot UK, Socci ND, Ho AL, Ghossein R, Fagin JA.

Cancer Res. 2018 Aug 15;78(16):4642-4657. doi: 10.1158/0008-5472.CAN-17-1925. Epub 2018 May 14.

7.

Adrenal Metastasectomy in the Presence and Absence of Extraadrenal Metastatic Disease.

Russo AE, Untch BR, Kris MG, Chou JF, Capanu M, Coit DG, Chaft JE, D'Angelica MI, Brennan MF, Strong VE.

Ann Surg. 2019 Aug;270(2):373-377. doi: 10.1097/SLA.0000000000002749.

PMID:
29578911
8.

MENIN loss as a tissue-specific driver of tumorigenesis.

Li JWY, Hua X, Reidy-Lagunes D, Untch BR.

Mol Cell Endocrinol. 2018 Jul 5;469:98-106. doi: 10.1016/j.mce.2017.09.032. Epub 2017 Sep 28. Review.

PMID:
28965973
9.

Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During Active Surveillance.

Tuttle RM, Fagin JA, Minkowitz G, Wong RJ, Roman B, Patel S, Untch B, Ganly I, Shaha AR, Shah JP, Pace M, Li D, Bach A, Lin O, Whiting A, Ghossein R, Landa I, Sabra M, Boucai L, Fish S, Morris LGT.

JAMA Otolaryngol Head Neck Surg. 2017 Oct 1;143(10):1015-1020. doi: 10.1001/jamaoto.2017.1442.

10.

Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of MED12 and RBM10 as Novel Thyroid Cancer Genes Associated with Tumor Virulence.

Ibrahimpasic T, Xu B, Landa I, Dogan S, Middha S, Seshan V, Deraje S, Carlson DL, Migliacci J, Knauf JA, Untch B, Berger MF, Morris L, Tuttle RM, Chan T, Fagin JA, Ghossein R, Ganly I.

Clin Cancer Res. 2017 Oct 1;23(19):5970-5980. doi: 10.1158/1078-0432.CCR-17-1183. Epub 2017 Jun 20.

11.

The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society.

Howe JR, Cardona K, Fraker DL, Kebebew E, Untch BR, Wang YZ, Law CH, Liu EH, Kim MK, Menda Y, Morse BG, Bergsland EK, Strosberg JR, Nakakura EK, Pommier RF.

Pancreas. 2017 Jul;46(6):715-731. doi: 10.1097/MPA.0000000000000846. Review.

12.

Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug.

Reidy-Lagunes DL, Lung B, Untch BR, Raj N, Hrabovsky A, Kelly C, Gerst S, Katz S, Kampel L, Chou J, Gopalan A, Saltz LB.

Oncologist. 2017 Sep;22(9):1102-1106. doi: 10.1634/theoncologist.2016-0459. Epub 2017 May 30.

13.

Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated.

Raj N, Valentino E, Capanu M, Tang LH, Basturk O, Untch BR, Allen PJ, Klimstra DS, Reidy-Lagunes D.

Pancreas. 2017 Mar;46(3):296-301. doi: 10.1097/MPA.0000000000000735.

14.

Complete metastasectomy for renal cell carcinoma: Comparison of five solid organ sites.

Jakubowski CD, Vertosick EA, Untch BR, Sjoberg D, Wei E, Palmer FL, Patel SG, Downey RJ, Strong VE, Russo P.

J Surg Oncol. 2016 Sep;114(3):375-9. doi: 10.1002/jso.24327. Epub 2016 Jun 23.

15.

Observation versus Resection for Small Asymptomatic Pancreatic Neuroendocrine Tumors: A Matched Case-Control Study.

Sadot E, Reidy-Lagunes DL, Tang LH, Do RK, Gonen M, D'Angelica MI, DeMatteo RP, Kingham TP, Groot Koerkamp B, Untch BR, Brennan MF, Jarnagin WR, Allen PJ.

Ann Surg Oncol. 2016 Apr;23(4):1361-70. doi: 10.1245/s10434-015-4986-1. Epub 2015 Nov 23.

16.

Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.

Tang LH, Untch BR, Reidy DL, O'Reilly E, Dhall D, Jih L, Basturk O, Allen PJ, Klimstra DS.

Clin Cancer Res. 2016 Feb 15;22(4):1011-7. doi: 10.1158/1078-0432.CCR-15-0548. Epub 2015 Oct 19. Erratum in: Clin Cancer Res. 2016 Aug 15;22(16):4273.

17.

NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition.

Garcia-Rendueles ME, Ricarte-Filho JC, Untch BR, Landa I, Knauf JA, Voza F, Smith VE, Ganly I, Taylor BS, Persaud Y, Oler G, Fang Y, Jhanwar SC, Viale A, Heguy A, Huberman KH, Giancotti F, Ghossein R, Fagin JA.

Cancer Discov. 2015 Nov;5(11):1178-93. doi: 10.1158/2159-8290.CD-15-0330. Epub 2015 Sep 10.

18.

Imaging and management of a small cell lung cancer metastasis/adrenal adenoma collision tumor: a case report and review of the literature.

Untch BR, Shia J, Downey RJ, Carrasquillo JA, Panicek DM, Strong VE.

World J Surg Oncol. 2014 Feb 26;12:45. doi: 10.1186/1477-7819-12-45. Review.

19.

Pathologic grade and tumor size are associated with recurrence-free survival in patients with duodenal neuroendocrine tumors.

Untch BR, Bonner KP, Roggin KK, Reidy-Lagunes D, Klimstra DS, Schattner MA, Fong Y, Allen PJ, D'Angelica MI, DeMatteo RP, Jarnagin WR, Kingham TP, Tang LH.

J Gastrointest Surg. 2014 Mar;18(3):457-62; discussion 462-3. doi: 10.1007/s11605-014-2456-x. Epub 2014 Jan 22.

PMID:
24448999
20.

Oncologic outcomes after completion thyroidectomy for patients with well-differentiated thyroid carcinoma.

Untch BR, Palmer FL, Ganly I, Patel SG, Michael Tuttle R, Shah JP, Shaha AA.

Ann Surg Oncol. 2014 Apr;21(4):1374-8. doi: 10.1245/s10434-013-3428-1. Epub 2013 Dec 24.

PMID:
24366419
21.

Pancreatic metastasectomy: the Memorial Sloan-Kettering experience and a review of the literature.

Untch BR, Allen PJ.

J Surg Oncol. 2014 Jan;109(1):28-30. doi: 10.1002/jso.23460. Epub 2013 Oct 7. Review.

PMID:
24122337
22.

Prophylactic central neck dissection in differentiated thyroid cancer: an assessment of the evidence.

Gyorki DE, Untch B, Tuttle RM, Shaha AR.

Ann Surg Oncol. 2013 Jul;20(7):2285-9. doi: 10.1245/s10434-013-2897-6. Epub 2013 Feb 16. Review.

PMID:
23417435
23.

Tumor proximity to the recurrent laryngeal nerve in patients with primary hyperparathyroidism undergoing parathyroidectomy.

Untch BR, Adam MA, Danko ME, Barfield ME, Dixit D, Scheri RP, Olson JA.

Ann Surg Oncol. 2012 Nov;19(12):3823-6. doi: 10.1245/s10434-012-2495-z. Epub 2012 Jul 31.

PMID:
22847120
24.

Surgeon-performed ultrasound is superior to 99Tc-sestamibi scanning to localize parathyroid adenomas in patients with primary hyperparathyroidism: results in 516 patients over 10 years.

Untch BR, Adam MA, Scheri RP, Bennett KM, Dixit D, Webb C, Leight GS Jr, Olson JA Jr.

J Am Coll Surg. 2011 Apr;212(4):522-9; discussion 529-31. doi: 10.1016/j.jamcollsurg.2010.12.038.

25.

Regulator of G protein signaling 5 is highly expressed in parathyroid tumors and inhibits signaling by the calcium-sensing receptor.

Koh J, Dar M, Untch BR, Dixit D, Shi Y, Yang Z, Adam MA, Dressman H, Wang X, Gesty-Palmer D, Marks JR, Spurney R, Druey KM, Olson JA Jr.

Mol Endocrinol. 2011 May;25(5):867-76. doi: 10.1210/me.2010-0277. Epub 2011 Mar 10.

26.

Severe obesity is associated with symptomatic presentation, higher parathyroid hormone levels, and increased gland weight in primary hyperparathyroidism.

Adam MA, Untch BR, Danko ME, Stinnett S, Dixit D, Koh J, Marks JR, Olson JA Jr.

J Clin Endocrinol Metab. 2010 Nov;95(11):4917-24. doi: 10.1210/jc.2010-0666. Epub 2010 Aug 4.

27.

Parathyroid carcinoma: current understanding and new insights into gene expression and intraoperative parathyroid hormone kinetics.

Adam MA, Untch BR, Olson JA Jr.

Oncologist. 2010;15(1):61-72. doi: 10.1634/theoncologist.2009-0185. Epub 2010 Jan 5. Review.

28.

Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care.

Tebbit CL, Zhai J, Untch BR, Ellis MJ, Dressman HK, Bentley RC, Baker JA, Marcom PK, Nevins JR, Marks JR, Olson JA Jr.

Breast Cancer Res Treat. 2009 Dec;118(3):635-43. doi: 10.1007/s10549-008-0301-1. Epub 2009 Feb 18.

29.

Vitamin D deficiency and primary hyperparathyroidism: an association of uncertain cause and consequences.

Untch BR, Olson JA.

Surgery. 2008 Dec;144(6):860-1. doi: 10.1016/j.surg.2008.10.005. No abstract available.

PMID:
19040988
30.

Inflammatory and hemostatic activation in patients undergoing off-pump coronary artery bypass grafting.

Untch BR, Jeske WP, Schwartz J, Botkin S, Prechel M, Walenga JM, Bakhos M.

Clin Appl Thromb Hemost. 2008 Apr;14(2):141-8. Epub 2007 Dec 26.

PMID:
18160569
31.

Impact of 25-hydroxyvitamin D deficiency on perioperative parathyroid hormone kinetics and results in patients with primary hyperparathyroidism.

Untch BR, Barfield ME, Dar M, Dixit D, Leight GS Jr, Olson JA Jr.

Surgery. 2007 Dec;142(6):1022-6.

PMID:
18063090
32.

Management of hemostasis in vascular surgery.

Untch BR, Turek JW, Manson RJ, Lawson JH.

Surgery. 2007 Oct;142(4 Suppl):S26-33. Review.

PMID:
18019943
33.

Minimally invasive radio-guided surgery for primary hyperparathyroidism.

Untch BR, Barfield ME, Bason J, Olson JA Jr.

Ann Surg Oncol. 2007 Dec;14(12):3401-2. Epub 2007 Sep 27.

PMID:
17899291
34.

Anaplastic thyroid carcinoma, thyroid lymphoma, and metastasis to thyroid.

Untch BR, Olson JA Jr.

Surg Oncol Clin N Am. 2006 Jul;15(3):661-79, x. Review.

PMID:
16882503
35.

Neoadjuvant chemoradiotherapy for locally advanced esophageal cancer: experience at a single institution.

Malaisrie SC, Untch B, Aranha GV, Mohideen N, Hantel A, Pickleman J.

Arch Surg. 2004 May;139(5):532-8; discussion 538-9.

PMID:
15136354
36.

Differential prevalence of anti-heparin-PF4 immunoglobulin subtypes in patients treated with clivarin and heparin: implications in the HIT pathogenesis.

Ahmad S, Untch B, Haas S, Hoppensteadt DA, Misselwitz F, Messmore HL, Walenga JM, Fareed J.

Mol Cell Biochem. 2004 Mar;258(1-2):163-70.

PMID:
15030181
37.

Development of a non-human primate sub-clinical model of heparin-induced thrombocytopenia: platelet responses to human anti-heparin-platelet factor 4 antibodies.

Untch B, Ahmad S, Messmore HL, Schultz CL, Ma Q, Hoppensteadt DA, Walenga JM, Fareed J.

Thromb Res. 2002 Apr 15;106(2):149-56.

PMID:
12182915
38.
39.

Ecarin clotting time is sensitive to heparinoids: comparison of two different techniques.

Demir M, Iqbal O, Untch B, Hoppensteadt DA, Gaikwad BS, Fareed J.

Clin Appl Thromb Hemost. 2001 Jan;7(1):38-43.

PMID:
11190903

Supplemental Content

Support Center